
Sign up to save your podcasts
Or


In episode 584, Mike and James invite Tina Korownyk back to the podcast to talk about the evidence for amyloid-targeting monoclonal antibodies in mild cognitive impairment or Alzheimer’s dementia. Unfortunately, the evidence shows these medications don’t seem to have a clinically important effect and do have some harms. Have a listen as we give you all the numbers so you will be able to properly discuss these medications with your patients.
Show notes
Tools for Practice
By James McCormack4.6
165165 ratings
In episode 584, Mike and James invite Tina Korownyk back to the podcast to talk about the evidence for amyloid-targeting monoclonal antibodies in mild cognitive impairment or Alzheimer’s dementia. Unfortunately, the evidence shows these medications don’t seem to have a clinically important effect and do have some harms. Have a listen as we give you all the numbers so you will be able to properly discuss these medications with your patients.
Show notes
Tools for Practice

550 Listeners

700 Listeners

499 Listeners

112 Listeners

291 Listeners

298 Listeners

261 Listeners

3,349 Listeners

1,157 Listeners

606 Listeners

196 Listeners

512 Listeners

253 Listeners

100 Listeners

373 Listeners